Read our latest updates & insights

On 20 May 2026, The Economics Times reported that Zydus Lifesciences plans to commercialise its generic semaglutide formulation across more than 20 markets over the next two years.

Zydus was one of the first companies to launch generic semaglutide in India (marketed ...

On 20 May 2026, Korea Biomedical Review reported that Korea’s Ministry of Food and Drug Safety has approved MSD’s Keytruda SC™ (pembrolizumab and berahyaluronidase alfa) for 35 indications across 18 cancer types.  MSD plans to launch the product in Korea in Q4/2026.

...

On 19 May 2026, Formycon and Klinge Biopharma announced that the European launch of FYB203, biosimilar to Regeneron/Bayer’s Eylea® (aflibercept, 2mg), commenced on 15 May 2026 in key European markets, including Germany, France and Italy.

The launch follows a March 20...

On 18 May 2026, Accord BioPharma announced that the FDA has approved Immgolis™ and Immgolis Intri™ (golimumab) as interchangeable biosimilars to Janssen’s Simponi® and Simponi® Aria, respectively.  These are the first golimumab biosimilars to be approved in the US.

T...

On 15 May 2026, Roche subsidiary Genentech announced that the FDA has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) as adjuvant treatment for adults with muscle-invasive bladder cancer (MIBC) who have circulating tumour DNA ...

On 15 May 2026, the FDA approved BMS/Daiichi Sankyo’s Enhertu® (fam-trastuzumab deruxtecan-nxki) for two separate breast cancer indications.  The indications are:

followed, by taxane, trastuzumab and pertuzumab (THP) for neoadjuvant treatment of adults with HER-2 p...

On 15 May 2026, Sandoz announced that the European Commission has granted marketing authorisation for Bysumlog®, biosimilar to Eli Lilly’s Humalog® (insulin lispro), and Dazparda®, biosimilar to Novo Nordisk’s NovoRapid® (insulin aspart).  Both biosimilars are approved for ...

On 15 May 2026, Alteogen announced that the Korean Ministry of Food and Drug Safety (MFDS) has granted marketing authorisation for Eyzanfy™/ALT-L9 (aflibercept), biosimilar to Regeneron/Bayer’s Eylea® 2mg, for all approved reference indications.  The approval comes 20 month...